Fever control in critically ill adults. An individual patient data meta-analysis of randomised controlled trials
One potential way to protect patients from the physiological demands that are a consequence of fever is to aim to prevent fever and to treat it assiduously when it occurs. Our primary hypothesis was that more active fever management would increase survival among patient subgroups with limited physiological reserves such as older patients, patients with higher illness acuity, and those requiring organ support.
We conducted an individual-level patient data meta-analysis of randomised controlled trials to compare the outcomes of ICU patients who received more active fever management with the outcomes of patients who received less active fever management. The primary outcome variable of interest was the unadjusted time to death after randomisation.
Of 1413 trial participants, 707 were assigned to more active fever management and 706 were assigned to less active fever management. There was no statistically significant heterogeneity in the effect of more active compared with less active fever management on survival in any of the pre-specified subgroups that were chosen to identify patients with limited physiological reserves. Overall, more active fever management did not result in a statistically significant difference in survival time compared with less active fever management [hazard ratio 0.91; (95% CI 0.75–1.10), P = 0.32].
Our findings do not support the hypothesis that more active fever management increases survival compared with less active fever management overall or in patients with limited physiological reserves.
KeywordsSepsis Fever Septic shock Paracetamol Non-steroidal anti-inflammatory drugs Physical cooling
This research was conducted during the tenure of a Clinical Practitioner Research Fellowship from the Health Research Council of New Zealand held by PY. The Medical Research Institute of New Zealand is supported by independent research organisation funding from the Health Research Council of New Zealand.
Compliance with ethical standards
Conflicts of interest
Dr. Paul Young and Dr. Manoj Saxena report receiving speaker’s fees from Bard Medical Pty. Dr. Gordon Bernard reports having an equity stake and is on the Board of Directors for Cumberland Pharmaceuticals, Nashville, TN, makers of intravenous ibuprofen (Caldolor).
An approval by an ethics committee was not applicable.
- 6.Young P, Saxena M, Bellomo R, Freebairn R, Hammond N, van Haren F, Holliday M, Henderson S, Mackle D, McArthur C, McGuinness S, Myburgh J, Weatherall M, Webb S, Beasley R (2015) Acetaminophen for fever in critically ill patients with suspected infection. N Engl J Med 373:2215–2224PubMedGoogle Scholar
- 7.Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, Dupont WD, Higgins SB, Swindell BB (1997) The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 336:912–918PubMedGoogle Scholar
- 13.Metnitz PG, Moreno RP, Almeida E, Jordan B, Bauer P, Campos RA, Iapichino G, Edbrooke D, Capuzzo M, Le Gall JR (2005) SAPS 3—from evaluation of the patient to evaluation of the intensive care unit. Part 1: Objectives, methods and cohort description. Intensive Care Med 31:1336–1344PubMedGoogle Scholar
- 17.Young PJ, Saxena M, Beasley R, Bellomo R, Bailey M, Pilcher D, Finfer S, Harrison D, Myburgh J, Rowan K (2012) Early peak temperature and mortality in critically ill patients with or without infection. Intensive Care Med 38:437–444Google Scholar